证券代码：300357 证券简称：我武生物 公告编号：2023-035 号 浙江我武生物科技股份有限公司 第五届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江我武生物科技股份有限公司（以下简称"公司"）第五届董事会第三次会议通 知于 2023 年 8 月 14 日以邮件方式发出。会议于 2023 年 8 月 24 日在公司上海分公司会 议室（上海市钦江路 333 号 40 号楼 5 楼）以现场结合通讯表决方式召开。会议应出席 董事 6 人，实际出席董事 6 人（其中：以通讯表决方式出席会议 1 人），董事胡赓熙、 陈燕霓（YANNI CHEN）、徐国良、张飞达（ZHANG FEIDA）、张露以现场表决方式出 席会议，董事毕自强以通讯表决方式出席会议。会议由董事长胡赓熙先生召集并主持， 公司部分监事、高级管理人员列席了会议。本次会议的召集、召开符合《中华人民共和 国公司法》等有关法律、行政法规、部门规章、规范性文件和《公司章程》的规定。 经与会董事认真审议，通过如下决议： （一）审议通过《公司 2023 年 ...

浙江我武生物科技股份有限公司 （本页无正文，为《浙江我武生物科技股份有限公司第五届董事会第三次会议 独立董事对相关事项的独立意见》之签字页） 独立董事： 经核查，报告期内（2023 年 1 月 1 日至 2023 年 6 月 30 日），公司控股股东及 其他关联方不存在占用公司资金的情况，也不存在以前年度发生并累积至报告期的 控股股东及其他关联方违规占用公司资金的情况。 2、关于公司对外担保情况的说明和独立意见 经核查，报告期内（2023 年 1 月 1 日至 2023 年 6 月 30 日），公司严格遵守相 关要求和规定，未发生对外担保事项，不存在通过对外担保损害公司及其他股东利 益的情形，也不存在以前年度发生并延续到本报告期的对外担保情况。 （以下无正文，后附签字页） 第五届董事会第三次会议 独立董事对相关事项的独立意见 根据《中华人民共和国公司法》、《中华人民共和国证券法》、中国证监会《上市 公司独立董事规则》、《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》等相关法律、法规、规 范性文件和《公司章程》、《独立董事制度》的相关规定，我们作 ...

经与会监事认真审议，通过如下决议： 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、监事会会议召开情况 浙江我武生物科技股份有限公司（以下简称"公司"）第五届监事会第三次会议通 知于 2023 年 8 月 14 日以邮件方式发出。会议于 2023 年 8 月 24 日在公司上海分公司会 议室（上海市钦江路 333 号 40 号楼 5 楼）以现场方式召开。会议应出席监事 3 人，实 际出席监事3人。会议由监事会主席金桃女士召集并主持，公司董事会秘书列席了会议。 本次会议的召集、召开符合《中华人民共和国公司法》等有关法律、行政法规、部门规 章、规范性文件和《公司章程》的规定。 二、监事会会议审议情况 证券代码：300357 证券简称：我武生物 公告编号：2023-036 号 浙江我武生物科技股份有限公司 第五届监事会第三次会议决议公告 （一）审议通过《公司 2023 年半年度报告及其摘要》 经审核，监事会认为董事会编制和审核的《公司 2023 年半年度报告全文》与《公 司 2023 年半年度报告摘要》的程序符合法律、行政法规和中国证监会的规定，报告内 容真实、 ...

浙江我武生物科技股份有限公司 第四条 董事会秘书的任职资格： (一) 应当由公司董事、副总经理、财务负责人或者公司章程规定的其他高级 管理人员担任； 拟聘任董事会秘书因涉嫌犯罪被司法机关立案侦查或者涉嫌违法违规被中国 证监会立案调查，尚未有明确结论意见的，公司应当及时披露拟聘任该人士的 原因以及是否存在影响公司规范运作的情形，并提示相关风险。 董事会秘书工作制度 （2023 年 8 月） 第一章 总则 第二章 董事会秘书任职资格和任免 1 第一条 为进一步完善浙江我武生物科技股份有限公司(以下简称"公司")治理结构，明 确董事会秘书的权利义务和职责，依照《中华人民共和国公司法》(以下简称"《公 司法》")、《中华人民共和国证券法》(以下简称"《证券法》")、《深圳证 券交易所创业板股票上市规则》(以下简称"《上市规则》")、《深圳证券交易 所上市公司自律监管指引第2号——创业板上市公司规范运作》（以下简称《规 范运作》）和《浙江我武生物科技股份有限公司章程》(以下简称"公司章程") 及其他有关规定，制定本制度。 第二条 公司董事会设董事会秘书一名。董事会秘书为公司的高级管理人员，对公司和 董事会负责，承担法律 ...

关于董事、高级管理人员减持计划期限届满的公告 证券代码：300357 证券简称：我武生物 公告编码：2023-033 号 股东张露女士保证向本公司提供的信息内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 浙江我武生物科技股份有限公司 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 张露女士本次减持公司股份计划已进行了预披露，本次减持计划符合《公司 法》、《证券法》、《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市 公司自律监管指引第 2 号——创业板上市公司规范运作》、中国证监会《上市公 司股东、董监高减持股份的若干规定》、深圳证券交易所《上市公司股东及董监 高减持股份实施细则》等法律法规及规范性文件的规定。截至 2023 年 8 月 9 日， 张露女士未减持公司股份，不存在违反此前已披露的意向、承诺及减持计划的情 形。 三、备查文件 1、张露女士出具的《股份减持情况告知函》； 1 浙江我武生物科技股份有限公司（以下简称"公司"）于 2023 年 1 月 12 日 披露了《关于董事、高级管理人员减持计划的预披露公告》（公告编号：2023-001 号），公司董事、副总 ...

证券代码：300357 证券简称：我武生物 浙江我武生物科技股份有限公司投资者关系活动记录表 编号：2023-005 投资者关系活 ■特定对象调研 □分析师会议 □媒体采访 动类别 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他（分析师电话会议） 参与单位名称 国泰基金：邓时锋；盈联资本：应振洲；惠正私募：訾力强；嘉 及人员姓名 实基金：李慧；东方红：马庆华；中欧基金：赵磊；海通证券： 彭聘；兴业证券：东楠；广发基金：王瑞冬；奥博资本：星璇； 汇添富：谢杰；德邦证券：吴沛柯；国君证券：谈嘉程。 时间 2023 年 6 月 16 日 16:00-17:30 地点 浙江省台州市仙居县白塔镇迎仙路 2 号二楼会议室 上市公司接待 董事长/总经理：胡赓熙；副总经理/董事会秘书：管祯玮；市场 人员姓名 部副经理：季龙。 1、 公司产品"黄花蒿花粉变应原舌下滴剂"和"粉尘螨滴剂" 使用时间和见效时间是否一致？ 粉尘螨是全年性过敏原，黄花蒿花粉是季节性过敏原（夏秋 季花粉），所以评估两个产品疗效需要的时间是不同的。"粉尘螨 滴剂"在使用过程中会逐渐见到疗效，而"黄花蒿花粉变应原舌 投资者关系活 下滴剂"的疗效需 ...

证券代码：300357 证券简称：我武生物 编号：2023-004 投资者关系活 □特定对象调研 □分析师会议 □媒体采访 动类别 ■业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他（分析师电话会议） 通过全景网"投资者关系互动平台"（http://ir.p5w.net）参与本次年 参与单位名称 及人员姓名 度业绩说明会的投资者 时间 2023 年 5 月 6 日 9:30-11:00 地点 网上业绩说明会（全景网"投资者关系互动平台"） 上市公司接待 董事长/总经理：胡赓熙；独立董事：张飞达（ZHANG FEIDA）； 人员姓名 副总经理/董事会秘书：管祯玮；财务负责人：王国其 提问 1：1、从黄花蒿花粉变应原舌下滴剂库存量看，业务开 展及销售增长是否严重低于公司预期？除了加大学术推广及销 售力度外，公司是否会回顾一下黄花蒿花粉变应原舌下滴剂的定 价策略？2、公司前 5 大销售客户销售金额占比 45.34%，是否存 在经营风险？ 答：投资者您好！"黄花蒿花粉变应原舌下滴剂"目前仍处 投资者关系活 于早期推广销售阶段，该品种的定价是综合考虑了目前市场竞争 动主要内容介 环境、未来通胀等诸多因素。公司前 ...

Revenue and Profitability - The company's total revenue for the first quarter was approximately ¥197.59 million, with a net profit attributable to shareholders of ¥91.74 million[41]. - In the second quarter, revenue reached approximately ¥191.32 million, with a net profit attributable to shareholders of ¥89.35 million[41]. - The third quarter saw revenue increase to approximately ¥311.28 million, with a net profit attributable to shareholders of ¥146.13 million[41]. - The fourth quarter's revenue was approximately ¥195.84 million, with a net profit attributable to shareholders of ¥21.56 million[41]. - The net profit after deducting non-recurring gains and losses for the entire year was approximately ¥76.73 million in Q1, ¥77.30 million in Q2, ¥139.04 million in Q3, and ¥21.49 million in Q4[41]. - The company's operating revenue for 2022 was ¥896,016,141.32, representing a 10.94% increase compared to ¥807,691,606.00 in 2021[59]. - The net profit attributable to shareholders for 2022 was ¥348,773,471.01, a 3.19% increase from ¥337,991,284.82 in 2021[59]. - The company's total comprehensive income for the year was approximately CNY 335.75 million, a decrease from CNY 352.23 million in the previous year, reflecting a decline of about 4.2%[75]. - Basic and diluted earnings per share increased to CNY 0.6661 from CNY 0.6455, representing a growth of approximately 3.5%[75]. Product Development and Innovation - The company is focusing on the development of natural medicines to combat antibiotic-resistant bacteria, indicating a strategic shift towards innovative drug discovery[51]. - The company is actively expanding its research and development capabilities in the field of natural medicines, which is expected to yield promising market prospects[52]. - The company completed the III phase clinical trial for the "Artemisia annua pollen sublingual drops" for children, which is currently in the CDE technical review stage[96]. - The company has initiated preclinical research for a second stem cell therapy drug aimed at treating osteoarthritis[98]. - The company’s first stem cell therapy drug for osteoporosis has passed quality review and is under submission to the National Health Commission[98]. - The company aims to enter new major medical product fields, including stem cell therapy and natural medicines, targeting the formation of new product clusters in 2-3 therapeutic areas over the next decade[161]. - Ongoing clinical trials include the III phase for "Pollen Extract Injection" and I phase for "Dermatitis Diagnostic Patch," with preclinical research on stem cell therapy products also in progress[164]. Market Position and Strategy - The company maintains a leading position in the domestic market for sublingual immunotherapy products, with its "Dust Mite Drops" and "Artemisia Pollen Sublingual Drops" being the only approved products[50]. - The biopharmaceutical industry in China is experiencing rapid growth, driven by increasing healthcare demands and government support, which presents significant opportunities for the company[47]. - The company is adapting to market changes by enhancing hospital coverage and academic marketing while controlling costs[6]. - The company is focusing on academic marketing strategies to increase product promotion and market penetration[90]. - The company plans to enhance its sales network, particularly in northern China, to better align with regional economic development and market demand[164]. Financial Management and Investments - The company reported a cash flow from operating activities of ¥360,279,064.78, a slight decrease of 0.08% compared to ¥360,575,120.69 in 2021[59]. - The company has established a self-sufficient stem cell culture system and developed a series of core technologies in the stem cell field, indicating a focus on innovation and market expansion[73]. - The company reported cash inflows from investment activities of CNY 566.86 million, down from CNY 754.99 million, reflecting a decrease of approximately 25%[77]. - The net cash flow from investment activities was negative at CNY -118.19 million, an improvement from CNY -212.31 million in the previous year[77]. - The company has a total of 65.81 million yuan in surplus raised funds, primarily due to strict procurement controls and cost reductions during project implementation[175]. - The company terminated the "Marketing Network Expansion and Information Technology Construction Project," resulting in a permanent allocation of 28.88 million yuan in surplus funds to working capital[175]. Risk Management and Regulatory Compliance - The company faces risks related to concentrated main products, as the sales of "Dust Mite Drops" largely determine overall profitability[28]. - The company acknowledges the risk of industry policy changes and plans to actively implement measures to control operational risks[24]. - The company is facing regulatory challenges due to tightening drug management laws, which may impact the drug registration process and overall market competitiveness[167]. - The company has established a governance structure that complies with relevant laws and regulations, enhancing its internal control systems[172]. - The company has implemented measures to monitor industry policy changes to mitigate operational risks[195]. Research and Development Expenditure - Total R&D investment for the year was ¥116,665,722.78, accounting for 13.02% of operating revenue[93]. - The company is actively expanding its R&D efforts into stem cells and natural medicines, with specific investments of ¥56,782,780.57 and ¥12,981,322.98 respectively[93]. - R&D expenses rose by 20.58% to ¥106,019,343.61, indicating a significant investment in innovation[122]. - The capitalized R&D expenditure accounted for 9.13% of total R&D investment, down from 13.82% in the previous year[143]. Corporate Governance - The company completed the board of directors' re-election on December 28, 2022, with the new board serving a three-year term[192]. - The company has established a sound corporate governance structure, including a shareholders' meeting, board of directors, and supervisory board, ensuring effective oversight and compliance[200]. - The company has a supervisory board consisting of three members, including one employee representative, ensuring compliance with legal requirements[192]. - The company has not provided guarantees for its controlling shareholders, maintaining financial independence[200]. - The company ensures that all shareholders, especially minority shareholders, have equal rights and opportunities to participate in meetings[200].

Financial Performance - The company's operating revenue for Q1 2023 was ¥183,139,637.81, a decrease of 7.31% compared to the same period last year[8] - Net profit attributable to shareholders was ¥70,478,103.64, down 23.17% year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥67,924,569.47, a decrease of 11.48% compared to the previous year[8] - The company reported a total profit of ¥74,695,305.79, compared to ¥106,121,775.74 in the previous year, representing a decrease of 29.6%[33] - The net profit margin decreased to 36.2% from 46.4% year-over-year, highlighting a significant drop in profitability[33] - Basic and diluted earnings per share were both 0.1346, down from 0.1752 in the previous period[36] Cash Flow - The net cash flow from operating activities increased by 50.95% to ¥83,916,819.04 compared to the same period last year[8] - Cash inflow from operating activities totaled 233,270,208.98, slightly up from 229,210,561.85[36] - Net cash flow from operating activities increased to 83,916,819.04 from 55,592,478.71, representing a significant improvement[36] - Cash inflow from investment activities was 169,277,857.45, compared to 71,817,750.95 in the previous period[37] - Net cash flow from investment activities was -25,985,064.22, an improvement from -36,137,641.70[37] - Cash inflow from financing activities was 20,000,000.00, with net cash flow from financing activities at 18,155,668.39, compared to -1,029,911.15 previously[37] - The net increase in cash and cash equivalents was ¥57,660,630.02, reflecting a 313.03% increase compared to the same period last year[13] - The ending balance of cash and cash equivalents reached 486,872,767.67, compared to 298,128,769.36 at the end of the previous period[37] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,257,726,099.79, an increase of 2.72% from the end of the previous year[8] - The company's equity attributable to shareholders increased by 3.56% to ¥2,050,012,917.00 compared to the end of the previous year[8] - The company's total assets increased to ¥2,257,726,099.79 from ¥2,197,788,958.32, reflecting growth in financial stability[33] - The company's total liabilities decreased to RMB 163,682,765.73 from RMB 170,760,022.93, indicating a reduction of about 4.1%[24] - The company reported a decrease in accounts payable from RMB 7,682,719.29 to RMB 5,373,862.77, a decline of approximately 30.1%[24] - The company’s non-current liabilities increased slightly to RMB 69,759,246.60 from RMB 68,008,569.94, reflecting a growth of about 2.6%[24] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,133, with the largest shareholder holding 38.86% of the shares[14] - The total equity attributable to shareholders increased to ¥2,050,012,917.00 from ¥1,979,540,771.28, showing a growth of 3.5%[33] Other Income and Investments - The company reported a significant decrease in other income, down 94.46% to ¥12,999,996.60, primarily due to reduced government subsidies related to daily operations[13] - The company reported an investment income of ¥2,468,267.68, significantly up from ¥674,438.30 in the previous year, indicating improved investment performance[33] Clinical Trials and Research - The company received a formal acceptance notice from the National Medical Products Administration for its clinical trial application of "Yanqumei Point Injection" in February 2023[21] - The company initiated a clinical study for its "Dermatitis Diagnostic Patch 01" with the first subject enrolled in February 2023[21] Inventory and Current Assets - Total current assets decreased to RMB 1,464,063,377.89 from RMB 1,477,132,637.58, indicating a decline of about 0.9%[22] - The company's inventory increased to RMB 50,605,440.56 from RMB 48,410,643.38, representing a growth of approximately 4.9%[22] Audit Information - The company did not undergo an audit for the first quarter report[38]